Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zegalogue (Dasiglucagon) Details Hypoglycemia | Approved Quarterly sales | |
Dasiglucagon Details Congenital Hyperinsulinism | NDA Submission | |
Glepaglutide Details Short bowel syndrome | Phase 3 Data readout | |
Dasiglucagon Details Type 1 diabetes | Phase 3 Update | |
Dasiglucagon Details Type 1 diabetes | Phase 2 Data readout | |
BI 456906 (GLP-1/glucagon dual agonist) Details Type 2 diabetes | Phase 2 Data readout | |
Dapiglutide Details Obesity | Phase 2 Data readout | |
BI 456906 (GLP-1/glucagon dual agonist) Details Obesity, Non-alcoholic steatohepatitis | Phase 2 Update | |
ZP8396 Details Obesity | Phase 1 Data readout | |
ZP6590 Details Obesity | Phase 1 Initiation |